公开(公告)号：US20230322898A1

公开(公告)日：2023-10-12

申请号：US18018807

申请日：2021-07-30

申请人： Chugai Seiyaku Kabushiki Kaisha ,  Yamaguchi University

发明人： Tomoyuki Igawa ,  Mika Sakurai ,  Takashi Suzuki ,  Kanako Tatsumi ,  Shun Shimizu ,  Koji Tamada ,  Yukimi Sakoda

IPC分类号： C07K16/30 ,  C12N15/86 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705 ,  A61K39/00

CPC分类号： C07K14/70578 ,  A61K39/4611 ,  A61K39/4637 ,  A61K39/464429 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/2818 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/303 ,  C12N15/86 ,  A61K2039/505 ,  A61K2239/22 ,  C07K2317/31 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2319/02 ,  C07K2319/33 ,  C12N2740/15043

摘要： The present invention provides a pharmaceutical composition comprising cells expressing a chimeric receptor, for use in combination with administration of an antigen-binding molecule, wherein the chimeric receptor comprises an extracellular domain, the extracellular domain comprises an extracellular domain of an immunoreceptor, an extracellular domain variant of an immunoreceptor, or a portion thereof, and the antigen-binding molecule is a multispecific antigen-binding molecule having a target antigen recognition site and an immunoreceptor recognition site which recognizes the immunoreceptor.

公开(公告)号：US20220143094A1

公开(公告)日：2022-05-12

申请号：US17603821

申请日：2020-04-17

申请人： Chugai Seiyaku Kabushiki Kaisha ,  Yamaguchi University

发明人： Mika Sakurai ,  Tomoyuki Igawa ,  Koji Tamada ,  Yukimi Sakoda

IPC分类号： A61K35/17 ,  C07K16/28 ,  C12N15/63

摘要： The present disclosure provides a pharmaceutical composition for use in combination with administration of a mutated antibody having a mutation, including substitution, deletion, addition or modification, of at least one amino acid in a CH1 region, a CH2 region, a CH3 region, a CL region, or a framework region, wherein the pharmaceutical composition comprises a cell expressing a chimeric receptor, the mutated antibody is capable of binding to the extracellular binding domain of the chimeric receptor via a moiety having the mutation, and the extracellular binding domain does not bind to an antibody free of the mutation.

公开(公告)号：US20220324975A1

公开(公告)日：2022-10-13

申请号：US17615748

申请日：2020-06-05

申请人： Chugai Seiyaku Kabushiki Kaisha ,  Yamaguchi University

发明人： Mika Sakurai ,  Tomoyuki Igawa ,  Yasunori Komori ,  Koji Tamada ,  Yukimi Sakoda

IPC分类号： C07K16/28 ,  A61K35/17

摘要： The present disclosure provides a pharmaceutical composition comprising an antibody having ADCC activity, a T cell-redirecting antibody, or a cell expressing a chimeric receptor, for use in combination with the administration of an antigen binding molecule capable of binding to a target antigen, wherein the primary molecule comprises a linker that is cleaved by protease, the antigen binding molecule obtained through the cleavage of the linker has the ability to bind to the target antigen, variable regions of the antibody having ADCC activity or the T cell-redirecting antibody, and an extracellular binding domain of the chimeric receptor bind to a cell expressing the target antigen via binding to the antigen binding molecule resulting from the cleavage of the cleavable linker.

公开(公告)号：US20210253726A1

公开(公告)日：2021-08-19

申请号：US17133286

申请日：2020-12-23

申请人： YAMAGUCHI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： C07K16/28 ,  A61K35/26 ,  A61K35/76 ,  C12N5/10 ,  C12N15/00 ,  C12N15/09 ,  A61K35/17 ,  C07K14/52 ,  C07K14/54 ,  C07K14/725 ,  C07K14/705 ,  C07K16/44 ,  C12N5/0783

摘要： An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells.
A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

公开(公告)号：US11337997B2

公开(公告)日：2022-05-24

申请号：US16084503

申请日：2017-03-15

申请人： YAMAGUCHI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/79

摘要： It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.

公开(公告)号：US11617765B2

公开(公告)日：2023-04-04

申请号：US16754645

申请日：2018-10-09

申请人： YAMAGUCHI UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi ,  Takafumi Nakamura

IPC分类号： A61K35/17 ,  A61P35/00

摘要： An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.

公开(公告)号：US20220273723A1

公开(公告)日：2022-09-01

申请号：US17748889

申请日：2022-05-19

申请人： Yamaguchi University

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/79

摘要： It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.

公开(公告)号：US10906984B2

公开(公告)日：2021-02-02

申请号：US16404165

申请日：2019-05-06

申请人： YAMAGUCHI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K48/00 ,  C12N15/00 ,  C12N15/63 ,  C07K16/28 ,  A61K35/26 ,  A61K35/76 ,  C12N5/10 ,  C12N15/09 ,  A61K35/17 ,  C07K14/52 ,  C07K14/54 ,  C07K14/725 ,  C07K14/705 ,  C07K16/44 ,  C12N5/0783 ,  A01K67/00 ,  C07K19/00 ,  C07K14/47

摘要： An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells.
A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

公开(公告)号：US20240269174A1

公开(公告)日：2024-08-15

申请号：US18166672

申请日：2023-02-09

申请人： Yamaguchi University ,  National University Corporation Tottori University

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi ,  Takafumi Nakamura

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/725

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/521 ,  C07K14/5418 ,  C07K14/7051

摘要： The present disclosure provides a composition comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and its use thereof.

公开(公告)号：US20240226157A1

公开(公告)日：2024-07-11

申请号：US18424245

申请日：2024-01-26

申请人： Yamaguchi University

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K35/17 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

CPC分类号： A61K35/17 ,  A61K39/0011 ,  C07K14/5418 ,  C07K14/7051 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

摘要： It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.